IMMUNOGLOBULIN, ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB22841 SINGLE-CHAIN VARIABLE FRAGMENT VH-LINKER-VL) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN C-REGION C-TERMINAL FRAGMENT), (257->230'),(260->233')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 ANTI-(HUMAN LYMPHOCYTE ACTIVATION GENE-3) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB22841 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL XMAB22841 .KAPPA.-CHAIN
Non-small Cell Lung Carcinoma
Xencor, Inc.monoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
1206 Active assets in the Non-small Cell Lung Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Necitumumab Jonsson Comprehensive Cancer Center | Phase 3 | BBB |
Zorifertinib Alpha Biopharma (Jiangsu) Co., Ltd. | Phase 2/3 | BBB |
Glumetinib Shanghai JMT-Bio Inc. | Phase 3 | BBB |
d-0316 Betta Pharmaceuticals Co., Ltd. | Phase 2/3 | BBB |
Onartuzumab Hoffmann-La Roche | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
IMMUNOGLOBULIN, ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB22841 SINGLE-CHAIN VARIABLE FRAGMENT VH-LINKER-VL) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN C-REGION C-TERMINAL FRAGMENT), (257->230'),(260->233')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 ANTI-(HUMAN LYMPHOCYTE ACTIVATION GENE-3) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB22841 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL XMAB22841 .KAPPA.-CHAIN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →